“Our partnership with AstraZeneca allows us to explore new and potentially transformational treatment combinations in haematological and solid tumours. Both parties bring deep scientific expertise, and by sharing this we’re expanding treatment options for patients.”

Bob Duggan, Chairman & Chief Executive Officer, Pharmacyclics

“There is a clear and significant unmet need in the treatment of blood cancers, an area of increasing focus for AstraZeneca. Our partnership with Pharmacyclics will allow us to explore new and potentially potent treatment combinations, which could have a positive impact on patient outcomes.”

Susan Galbraith, Head of the Oncology Innovative Medicines Unit, AstraZeneca

Strategic fit

• Highly complementary collaboration to combine assets that have potential to create an enhanced effect
• Strengthens companies’ scientific leadership in the immuno-oncology landscape
• Combination supports efforts to develop an enhanced immune response against haematological cancers, one of the four main areas of focus for AstraZeneca in oncology

Combination therapies in immuno-oncology have the potential to change the way we treat cancer. By targeting complementary pathways, establishing synergistic effects and helping to overcome resistance to monotherapy, they can help address the underlying mechanisms of the disease or explore how it evades effective immune response. This, in return, helps accelerate the delivery of targeted medicines to patients.

In November 2014, AstraZeneca entered into clinical trial collaborations with Pharmacyclics, Inc. to evaluate novel combination therapies targeting solid tumours and a number of haematological cancers. The partnership is an example of AstraZeneca’s strategic approach of exploring combinations that can help change the treatment paradigm for cancer patients.

The first collaboration focuses on solid tumours and evaluates the efficacy and safety of IMBRUVICA® (ibrutinib), Pharmacyclics’ oral Bruton’s tyrosine kinase inhibitor, in combination with AstraZeneca’s anti-PD-L1 antibody, MEDI4736.

The second collaboration focuses on haematological cancers and explores separate combinations of two different AstraZeneca investigational PI3 kinase pathway inhibitors with IMBRUVICA® for the treatment of patients with relapsed or refractory diffuse large B-cell lymphomas.

Deal structure

• Non-exclusive collaboration; both partners retain full rights for their respective intellectual property
• Multiple Phase I and Phase IIa studies may be considered and conducted, the results of which will be used to determine whether further clinical development of the different combinations is appropriate

Programme highlights

IMBRUVICA® has received marketing authorisation from the European Commission and Breakthrough Therapy Designations from the US FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL).